Advertisement
UK markets close in 7 hours 37 minutes

  • FTSE 100

    8,077.41
    +37.03 (+0.46%)
     

  • FTSE 250

    19,613.57
    -105.80 (-0.54%)
     

  • AIM

    753.82
    -0.87 (-0.12%)
     

  • GBP/EUR

    1.1665
    +0.0020 (+0.17%)
     

  • GBP/USD

    1.2504
    +0.0041 (+0.33%)
     

  • Bitcoin GBP

    51,217.32
    -2,214.77 (-4.15%)
     

  • CMC Crypto 200

    1,387.75
    +5.18 (+0.37%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CRUDE OIL

    82.98
    +0.17 (+0.21%)
     

  • GOLD FUTURES

    2,334.80
    -3.60 (-0.15%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • HANG SENG

    17,263.19
    +61.92 (+0.36%)
     

  • DAX

    17,995.33
    -93.37 (-0.52%)
     

  • CAC 40

    8,063.90
    -27.96 (-0.35%)
     
Property:

How to sell your home

Top tips from property investors

Express Scripts, the Good Guy on Drug Prices? Not Exactly

Max Nisen
Express Scripts, the Good Guy on Drug Prices? Not Exactly

Express Scripts Holding Co. is trying to lay low as regulators scrutinize Cigna Inc.’s plan to purchase the company. The pharmacy benefit manager (PBM) last week proposed a radical pricing shift for a new set of migraine medicines. You’d think these moves might soften regulators’ stance as they ponder the potential impact on consumers of the company’s $54 billion takeover by Cigna. But Express Scripts’ efforts to play the good guy may end up being good for appearances only.

Continue reading